Search results for "roe"

showing 10 items of 9822 documents

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

2018

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow microenvironment that favors immune escape. The Programmed Death-1 (PD-1) pathway is associated with the regulation of T cell activation and with the apoptotic pathways of effector memory T cells. Specifically, the binding with PD-1 ligand (PD-L1) on the surface of tumor plasma cells down-regulates T cell-proliferation, thus contributing to the immune escape of tumor cells. In relapsed and/or refr…

0301 basic medicinePD-L1lcsh:Immunologic diseases. AllergyDurvalumabMini ReviewT-LymphocytesT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationT cellsPembrolizumabmedicine.disease_causeB7-H1 Antigen03 medical and health sciences0302 clinical medicineBone Marrowimmune dysregulationPD-L1PD-1Tumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyImmune dysregulation; Multiple myeloma; PD-1; PD-L1; T cells; Animals; B7-H1 Antigen; Bone Marrow; Humans; Multiple Myeloma; Programmed Cell Death 1 Receptor; T-Lymphocytes; Tumor MicroenvironmentMultiple myelomabiologybusiness.industryImmune dysregulationmedicine.diseasemultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinCancer researchNivolumabbusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC)

2018

// Silvia Vecchiarelli 1, * , Francesco Passiglia 2, * , Armida D’Incecco 3, * , Marianna Gallo 4 , Antonella De Luca 4 , Elisa Rossi 5 , Federica D’Inca 1 , Gabriele Minuti 1 , Lorenza Landi 1 , Chiara Bennati 1 , Michela Spreafico 1 , Manolo D’Arcangelo 1 , Valentina Mazza 1 , Nicola Normanno 4 and Federico Cappuzzo 1 1 Department of Oncology and Hematology, AUSL della Romagna, Ravenna, Italy 2 Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy 3 Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy 4 Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione G Pascale"-IRCCS, Naples, Italy 5 Fond…

0301 basic medicinePD-L1medicine.medical_specialtymedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Gastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerSurvival analysisChemotherapyHematologybusiness.industrybiomarkersBiomarkermedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisCohortMann–Whitney U testImmunotherapybusinessNon-small-cell lung cancerResearch PaperProgrammed death
researchProduct

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

2020

Cancer immunotherapy utilizes the immune system to fight cancer and has already moved from the laboratory to clinical application. However, and despite excellent therapeutic outcomes in some hematological and solid cancers, the regular clinical use of cancer immunotherapies reveals major limitations. These include the lack of effective immune therapy options for some cancer types, unresponsiveness to treatment by many patients, evolving therapy resistance, the inaccessible and immunosuppressive nature of the tumor microenvironment (TME), and the risk of potentially life-threatening immune toxicities. Given the potential of nanotechnology to deliver, enhance, and fine-tune cancer immunothera…

0301 basic medicinePD-L1medicine.medical_treatmentimmune checkpoint inhibitorNanotechnologyReviewmacrophage03 medical and health sciencesMice0302 clinical medicineImmune systemDrug Delivery SystemsCancer immunotherapyPD-L1NeoplasmsPD-1MedicineAnimalsHumansNanotechnologytumor microenvironmentTreatment resistanceAdverse effecttoll like receptor (TLR)lcsh:QH301-705.5Tumor microenvironmentbiologybusiness.industryCancerGeneral Medicinemedicine.diseaseCombined Modality TherapyImmune therapy030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesissiRNAbiology.proteinCAR T cell therapymyeloid derived suppressor cells (MDSC)Immunotherapybusinessbi-specific antibody therapyCells
researchProduct

Acute Cortical Transhemispheric Diaschisis after Unilateral Traumatic Brain Injury

2017

Focal neocortical brain injuries lead to functional alterations, which can spread beyond lesion-neighboring brain areas. The undamaged hemisphere and its associated disturbances after a unilateral lesion, so-called transhemispheric diaschisis, have been progressively disclosed over the last decades; they are strongly involved in the pathophysiology and, potentially, recovery of brain injuries. Understanding the temporal dynamics of these transhemispheric functional changes is crucial to decipher the role of the undamaged cortex in the processes of functional reorganization at different stages post-lesion. In this regard, little is known about the acute-subacute processes after 24-48 h in th…

0301 basic medicinePatch-Clamp TechniquesTraumatic brain injurySomatosensory system03 medical and health sciences0302 clinical medicineCortex (anatomy)Unilateral lesionBrain Injuries TraumaticNeuroplasticitymedicineAnimalsDiaschisisNeuronal PlasticityMotor CortexElectroencephalographySomatosensory Cortexmedicine.diseaseMice Inbred C57BLDisease Models AnimalElectrophysiology030104 developmental biologymedicine.anatomical_structureBrain HemisphereNeurology (clinical)PsychologyNeuroscience030217 neurology & neurosurgeryJournal of Neurotrauma
researchProduct

TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer

2015

ABSTRACT In experimental mouse models of cancer, increasingly compelling evidence point toward a contribution of tumor associated macrophages (TAM) to tumor lymphangiogenesis. Corresponding experimental observations in human cancer remain scarce although lymphatic metastasis is widely recognized as a predominant route for tumor spread. We previously showed that, in malignant tumors of untreated breast cancer (BC) patients, TIE-2-expressing monocytes (TEM) are highly proangiogenic immunosuppressive cells and that TIE-2 and VEGFR signaling pathways drive TEM immunosuppressive function. We report here that, in human BC, TEM express the canonical lymphatic markers LYVE-1, Podoplanin, VEGFR-3 an…

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisTIE-2-expressing monocytesImmunologyBiology03 medical and health sciences0302 clinical medicineBreast cancerbreast cancermedicineImmunology and Allergytumor microenvironmentOriginal ResearchTumor microenvironmentKinaseCancermedicine.disease3. Good healthLymphangiogenesisTIE-2expressing monocytes030104 developmental biologyLymphatic systemOncologyPodoplaninlymphaticsAngiogenesis030215 immunology
researchProduct

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

2016

AbstractTreatment of high-risk childhood neuroblastoma is a clinical challenge which has been hampered by a lack of reliable neuroblastoma mouse models for preclinical drug testing. We have previously established invasive and metastasising patient-derived orthotopic xenografts (PDXs) from high-risk neuroblastomas that retained the genotypes and phenotypes of patient tumours. Given the important role of the tumour microenvironment in tumour progression, metastasis, and treatment responses, here we analysed the tumour microenvironment of five neuroblastoma PDXs in detail. The PDXs resembled their parent tumours and retained important stromal hallmarks of aggressive lesions including rich bloo…

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchStromal cellGenotypeTumour stromaBiologyPolymorphism Single NucleotideMetastasisMetastasisPaediatric cancer03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineNeuroblastomamedicineTumor MicroenvironmentAnimalsHumansPatient-derived xenograft (PDX)Tumor microenvironmentTumour microenvironmentNeovascularization Pathologicmedicine.diseaseXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologyLymphatic systemOncology030220 oncology & carcinogenesisCancer-Associated FibroblastsImmunohistochemistryBlood VesselsChildhood NeuroblastomaCancer letters
researchProduct

Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice.

2013

// Thorsten Maass 1 , Jens Marquardt 2 , Ju-Seog Lee 3 , Markus Krupp 4 , Peter Scholz-Kreisel 2 , Carolin Mogler 5 , Peter Schirmacher 5 , Martina Muller 1 , Heiner Westphal 6 , Peter R. Galle 2 , Andreas Teufel 1 1 Department of Internal Medicine I, University of Regensburg, Regensburg, Germany 2 I. Department of Medicine, University Medical Center Mainz, Mainz, Germany 3 Cancer Biology Program, MD Anderson Cancer Center, Houston, TX, USA 4 Department of Informatics, Johannes Gutenberg University Mainz, Mainz, Germany 5 Institute of Pathology, University of Heidelberg, Heidelberg, Germany 6 Laboratory of Mammalian Genes and Development, National Institute of Child Health and Human Develop…

0301 basic medicinePathologymedicine.medical_specialtyCarcinogenesisBiologymedicine.disease_causeTranscriptome03 medical and health sciencesMicestem cellsmedicineAtypiaAnimalsHumansGene Regulatory Networksprognostic signatureGeneWnt Signaling PathwayMice Knockouttranscriptomics profilingLiver CarcinogenesisDkk2Liver NeoplasmsGastroenterologyWnt signaling pathwaymedicine.diseaseMolecular biologyMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureOncologyHepatocyteCancer researchNeoplastic Stem CellsIntercellular Signaling Peptides and ProteinsStem cellLiver cancerCarcinogenesisgenetic signatureResearch PaperOncotarget
researchProduct

Optimized Mouse Models for Liver Fibrosis

2017

Fibrosis is the excessive accumulation of extracellular matrix components due to chronic injury, with collagens as predominant structural components. Liver fibrosis can progress to cirrhosis, which is characterized by a severe distortion of the delicate hepatic vascular architecture, the shunting of the blood supply away from hepatocytes and the resultant functional liver failure. Cirrhosis is associated with a highly increased morbidity and mortality and represents the major hard endpoint in clinical studies of chronic liver diseases. Moreover, cirrhosis is a strong cofactor of primary liver cancer. In vivo models are indispensable tools to study the cellular and molecular mechanisms of li…

0301 basic medicinePathologymedicine.medical_specialtyCirrhosisbusiness.industryLiver fibrosismedicine.diseaseVascular architectureExtracellular matrix03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryIn vivoFibrosisMedicine030211 gastroenterology & hepatologyThioacetamidebusinessPrimary liver cancer
researchProduct

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

2016

a b s t r a c t The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diag- nosis criteria, and new endpoints of clinical trials).…

0301 basic medicinePathologymedicine.medical_specialtyFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Gastroenterology; HepatologySystems AnalysisSystems biologyPersonalizedPopulationDiseaseBioinformatics03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineFatty liverNAFLDFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicinemedicineHumansFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Hepatology; GastroenterologyeducationFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Disease Progression; Humans; Non-alcoholic Fatty Liver Disease; Phenotype; Risk Factors; Systems Biology; Systems Analysis; Medicine (all); Hepatology; Gastroenterologyeducation.field_of_studyHepatologybusiness.industrySystems BiologySettore MED/09 - MEDICINA INTERNAFatty liverGastroenterologyNASHHepatologymedicine.diseaseSystems medicineClinical trial030104 developmental biologyPhenotypeSystems medicineDisease ProgressionMedicine030211 gastroenterology & hepatologySteatosisbusiness
researchProduct

Ewing's Sarcoma and Peripheral Primitive Neuroectodermal Tumor of Bone and Soft Tissue

1999

The histological diagnosis of Ewing's sarcoma (Es) continues to be a difficult task for pathologists. A number of new Es varieties has been described, leading to further complexity. Conventional Es, atypical Es, and peripheral neuroectodermal tumor (pPNET), including peripheral neuroepithelioma, belong genetically to the same family of neoplasms, displaying common chromosomal rearrangements and analogous gene reorganizations. The main translocations are t(11;22) and t(21;22), with genes EWS, FLI-1 and ERG being involved, as well as other members of the ETS family of transcription factors. The prevalence of morphology should be maintained with the use of conventional histological techniques…

0301 basic medicinePathologymedicine.medical_specialtyPeripheral Primitive Neuroectodermal TumorSoft tissueEwing's sarcomaBiologymedicine.diseasePathology and Forensic Medicine03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisHistological diagnosismedicineSurgerySarcomaAnatomyInternational Journal of Surgical Pathology
researchProduct